Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.z

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

Publications

Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR,

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

American journal of respiratory and critical care medicine 2010 Mar 15;181;604-10 — 2010 Mar 15 — 604-10

Yamasawa H, Sugiyama Y, Bando M, Ohno S

Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.

Respiration; international review of thoracic diseases 2008;75;350-4 — 2008 — 350-4